Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

The main objective of this study is to validate ClarityDX Prostate as a reflex test to PSA to refine the prediction of clinically-significant prostate cancer in a prospective cohort of men to be recruited in North America when they are scheduled for a biopsy as a result of on an elevated PSA or other suspicion of prostate cancer and in retrospective databases from selected sites in the United States of America and the world.

The training and validation analysis sets will consist of up to 2,800 consenting men from Alberta in addition to up to 5,000 men from external institutions, between ages 40-75 (inclusive) years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer.

Inclusion criteria

• Males between 40-75 (inclusive) years of age;
• With and without family history of prostate cancer;
• No prior prostate cancer diagnosis and who are referred to have a prostate biopsy;
• Total PSA results >/= 3ng/mL collected within 6m of enrollment;
• Willing to permit provincial agencies (e.g. Alberta Health Services, Alberta Health, Netcare, Service Alberta or other based on recruitment jurisdiction) to disclose health-related information to study;
• Undergoing a diagnostic prostate biopsy; and
• Provided informed consent to participate in the study.

Exclusion criteria

• Unwilling to participate in the study;
• Unavailable for biopsy procedure in recruitment areas;
• Not undergoing a prostate biopsy;
• Prior diagnosis of cancer excluding non-melanoma skin cancer; and/or
• Under the age of 40 years of age or over the age of 75 years of age.